Klin Farmakol Farm. 2011;25(3):122-125

Drug risk assessment: development of terminology

Milan Kriška
Ústav farmakológie a klinickej farmakológie Lekárskej fakulty Univerzity Komenského, Bratislava

The aim of this review is to inform the readers about the development of basic terminology of adverse drug reactions, pharmacovigilance

and risk monitoring for the needs of everyday clinical practice.

Keywords: adverce drug reactions, history, terminology, news

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kriška M. Drug risk assessment: development of terminology. Klin Farmakol Farm. 2011;25(3):122-125.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Edwards R, Wiholm BE, Martine C. Concepts in risk - benefit assessment. Drug Safety 1996; 15: 1-7. Go to original source... Go to PubMed...
    2. Drug benefits and risks eds. Boxtel CH, Santoso B, Edwards IR, 2nd Editions UMC collab WHO 2008: s747.
    3. Clark DVJ, Coulter DM, Besag FMC. Randomized controlrd trials and assesment of drugs. Drug Safety 2008; 31: 1057-1061. Go to original source... Go to PubMed...
    4. Aronson JK. Risk perception in drug therapy Br J Clin Pharmacol 2006; 62: 135-137. Go to original source... Go to PubMed...
    5. Edwards IR, Linquist M, Mayboom R. Olsen S Pharmacovigilance in focus Drug Safety 2005; 22: 90-386.
    6. Zápisnice komisie pre bezpečnosť liekov ŠUKL Bratislava 2010, 2011, www.sukl.sk.
    7. Mayboom RHB. Pharmacovigilance in a changing world. Klin Farmakol Farm 2011; 25(3): 102-111.
    8. Dušek J, Jezdinský J, Kroutil M, Lenfeld J, Malota H, Neoral L. Farmakoterapeutické riziko, Farmakoterapeutické správy SPOFA, 1975; (Suppl 3): 169.
    9. www ŠUKL Bratislava.
    10. www.health.sk.
    11. Royer RJ, Kriška M. Farmakovigilancia In: Riziko liekov v medicínskej praxi, Bratislava, SAP 2000: 43-49.
    12. Mayboom R, Linquist Marie, Egberts ACG. An ABC of drugrelated rpoblems. Drug Saferty 2000; 22: 415-423. Go to original source... Go to PubMed...
    13. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In Textbook of adverse reactions, ed Dawies, Oxford University Press 1977: 10.
    14. Edwards IR. Birriel C Harmonisation in pharmacovigilance Drug Safety 2005; 10: 93-102. Go to original source... Go to PubMed...
    15. www.who-UMC.org.
    16. Davie´s textbook of adverse drug reactions. Davies DM, Ferner RE, de Glanville H. eds, Chapman Hall Medical, 1998: 971.
    17. Maylers Side effects of drugs. JK Aronson editor, Elsevier Amsterodam, New York, 2006.
    18. Strom BL editor Pharmaepidemiology Chicester John Wiley and Sons, 2000: 874.
    19. WHO Adverse reaction terminology Dec 2002, Uppsala, The Uppsala Monitoring Centre.
    20. www.encepp.eu.
    21. Sentinel system FDA.com.
    22. Herret E, Thomas SL, Schoonen, et al. Validation and validity of diagnoses in the General Practice Research Databases (GRPD): a systematic review Br J Clin pharmacol 2010; 69: 4. Go to original source... Go to PubMed...
    23. Uppsala Conference, 40 Universary WHO ADR program, October 22: 2008.
    24. Gotze CP, Jorgensen AW. Opening data at the European Mediceines Agency BMJ 2011; 342: 26486-2690. Go to original source...
    25. Abstracts of the 1st Congress EACPT Paris, 1995; 27-30 Septembre, Therapie Suppl 1995: 191. Go to PubMed...
    26. ISOP Drug Safety.
    27. Urbánek K. Význam lékové politiky pro ŕízení velkých nemocnic. Klin. farmakol. farm. 2000: 14.
    28. Kriška M, Payer J, Novák I, Ježová D. Percepcia rizika liekov. Klin. farmakol. farm. 2003: 17(1): 12-16.
    29. Internat Conference on Harmonisation Guidance, www. FDA. Com.
    30. Communication patient safety during pharmacotherapy, Smolenice 200 May 21-22, reports in Rheumatológia 20010; 24: 69-104.
    31. Inman W, Pearce G. Prescribers profile and post - marketing surveillance. Lancet, 1993; 342: 658-661. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.